Influence of the Plasmodium falciparum P-glycoprotein homologue 1 (pfmdr1 gene product) on the antimalarial action of cyclosporin

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 2, 2007, Pages 197-203

  Gavigan, C S ^a,c   Shen, M ^b   Machado, S G ^b   Bell, A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Abbott Ireland Diagnostic Division   (Ireland)

Author keywords

Cyclosporin A; Malaria; Pgh1

Indexed keywords

ARTEMISININ; CHLOROQUINE; CYCLOSPORIN A; HALOFANTRINE; MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN 1; QUININE; ANTIMALARIAL AGENT; CYCLOSPORIN; MDR1 PROTEIN, PLASMODIUM FALCIPARUM; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TARGETING; GENE DUPLICATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE NUMBER; GENE OVEREXPRESSION; GENETIC CODE; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN INTERACTION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ANIMALS; ANTIMALARIALS; CYCLOSPORINE; DRUG RESISTANCE; DRUG SYNERGISM; GENE EXPRESSION REGULATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC;

EID: 33947492184     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl461     Document Type: Article

References (38)

1. Borel JF, Baumann G, Chapman I et al. In vivo pharmacological effects of cyclosporin and some analogues. Adv Pharmacol 1996; 35: 115-246.
2. Bell A, Roberts HC, Chappell LH. The antiparasite effects of cyclosporin A: Possible drug targets and clinical applications. Gen Pharmacol 1996; 27: 963-71.
3. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119-25.
4. Ke H, Huai Q. Crystal structures of cyclophilin and its partners. Front Biosci 2004; 9: 2285-96.
5. Bell A, Monaghan P, Page AP. Peptidyl-prolyl cis-trans isomerases (immunophilins) and their roles in parasite biochemistry, host-parasite interaction and antiparasitic drug action. Int J Parasitol 2006; 36: 261-76.
6. Hirtzlin J, Färber PM, Franklin RM et al. Molecular and biochemical characterization of a Plasmodium falciparum cyclophilin containing a cleavable signal sequence. Eur J Biochem 1995; 232: 765-72.
7. Berriman M, Fairlamb AH. Detailed characterization of a cyclophilin from the human malaria parasite Plasmodium falciparum. Biochem J 1998; 334: 437-45.
8. Gavigan CS, Kiely SP, Hirtzlin J et al. Cyclosporin-binding proteins of Plasmodium falciparum. Int J Parasitol 2003; 33: 987-96.
9. Kumar R, Musiyenko A, Barik S. Plasmodium falciparum calcineurin and its association with heat shock protein 90: Mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Mol Biochem Parasitol 2005; 141: 29-37.
10. Bell A, Wernli B, Franklin RM. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin. Biochem Pharmacol 1994; 48 495-503.
11. Ambudkar SV, Dey S, Hrycyna CA et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
12. Rosenberg MF, Callaghan R, Modok S et al. Three-dimensional structure of P-glycoprotein: The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem 2005; 280: 2857-62.
13. Teodori E, Dei S, Scapecchi S et al. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 2002; 57 385-415.
14. Loor F. Valspodar: Current status and perspectives. Expert Opin Investig Drugs 1999; 8: 807-35.
15. Waller KL, Lee S, Fidock DA. Molecular and cellular biology of chloroquine resistance in Plasmodium falciparum. In: Waters AP, Janse CJ, eds. Malaria Parasites: Genomes and Molecular Biolgy. Wymondham, UK: Caister Academic Press, 2004; 501-40.
16. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005; 94: 181-90.
17. Rubio JP, Cowman AF. The ATP-binding cassette (ABC) gene family of Plasmodium falciparum. Parasitol Today 1996; 12: 135-40.
18. Cowman AF, Karcz S, Galatis D et al. A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole. J Cell Biol 1991; 113: 1033-42.
19. Mu J, Ferdig MT, Feng X et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol 2003; 49: 977-89.
20. Mockenhaupt FP. Mefloquine resistance in Plasmodium falciparum. Parasitol Today 1995; 11: 248-53.
21. Reed MB, Saliba KJ, Caruana SR et al. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403: 906-9.
22. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol 2005; 57: 913-26.
23. Hayward R, Saliba KJ, Kirk K. Mutations in pfmdr1 modulate the sensitivity of Plasmodium falciparum to the intrinsic antiplasmodial activity of verapamil. Antimicrob Agents Chemother 2005; 49: 840-2.
24. Bell A. Antimalarial drug synergism and antagonism: Mechanistic and clinical significance. FEMS Microbiol Lett 2005; 253: 171-84.
25. Fennell BJ, Naughton JA, Dempsey E et al. Cellular and molecular actions of dinitroaniline and phosphorothioamidate herbicides on Plasmodium falciparum: Tubulin as a specific antimalarial target. Mol Biochem Parasitol 2006; 145: 226-38.
26. Bell A, Wernli B, Franklin RM. Effects of microtubule inhibitors on protein synthesis in Plasmodium falciparum. Parasitol Res 1993; 79: 146-52.
27. Makler MT, Ries JM, Williams JA et al. Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. Am J Trop Med Hyg 1993; 48: 739-41.
28. Nankya-Kitaka MF, Curley GP, Gavigan CS et al. Plasmodium chabaudi chabaudi and P. falciparum: Inhibition of aminopeptidase and parasite growth by bestatin and nitrobestatin. Parasitol Res 1998; 84: 552-8.
29. Gavigan CS, Machado SG, Dalton JP et al. Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling. Antimicrob Agents Chemother 2001; 45: 3175-81.
30. Machado SG, Robinson GA. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat Med 1994; 13: 2289-309.
31. Saliba KJ, Folb PI, Smith PJ. Role for the Plasmodium falciparum digestive vacuole in chloroquine resistance. Biochem Pharmacol 1998; 56: 313-20.
32. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 1994; 91: 1143-7.
33. Scheibel LW, Colombani PM, Hess AD et al. Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falciparum): Implications for drug design. Proc Natl Acad Sci USA 1987; 84: 7310-4.
34. Foxwell BM, Mackie A, Ling V et al. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989; 36: 543-6.
35. Demeule M, Wenger RM, Beliveau R. Molecular interactions of cyclosporin A with P-glycoprotein. Photolabeling with cyclosporin derivatives. J Biol Chem 1997; 272: 6647-52.
36. Rohrbach P, Sanchez CP, Hayton K et al. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J 2006; 25: 3000-11.
37. Karcz SR, Galatis D, Cowman AF. Nucleotide binding properties of a P-glycoprotein homologue from Plasmodium falciparum. Mol Biochem Parasitol 1993; 58: 269-76.
38. Foley M, Tilley L. Quinoline antimalarials: Mechanisms of action and resistance and prospects for new agents. Pharmacol Ther 1998; 79: 55-87.